Storyboard

Why the FDA's Approval of Biogen's Alzheimer's Drug is So Controversial

The first treatment against Alzheimer's Disease in nearly 20 years received the Food and Drug Administration's approval on Monday. However, the agency's decision is being scrutinized after an independent panel of experts declined to endorse the drug from Biogen pharmaceuticals. Scientists questioned the data from its clinical trials, saying it wasn't conclusive enough. And Biogen isn't the only drug maker with suspect data either.

Avatar - The Science Desk
Curated by
The Science Desk
    • Medicine
    • Scientific Research
    • Research
    • Life Sciences
    • Medical Conditions
Why the FDA's Approval of Biogen's Alzheimer's Drug is So Controversial
Continue to read
11 stories in this Storyboard
    FDA approves Biogen's Alzheimer's drug despite lack of evidence

    FDA approves Biogen's Alzheimer's drug despite lack of evidence

    The FDA has approved Biogen's Alzheimer's drug, aducanumab, which will be marketed as Aduhelm. Biogen is charging $56,000 per year for the drug. Why …

    FDA Poised For Decision On Controversial Alzheimer's Drug

    FDA Poised For Decision On Controversial Alzheimer's Drug

    verified_publisher
    NPR - Jon Hamilton

    A drug called aducanumab could become the first approved treatment designed to alter the course of Alzheimer's disease rather than relieve symptoms. But it's unclear whether the Food and Drug Administration will approve the drug because of persistent questions about its effectiveness. The FDA has a …

    Other Alzheimer's Drugs Being Reviewed

    Eli Lilly's Alzheimer's Drug Shows Promise in Small Trial
    1.

    Eli Lilly's Alzheimer's Drug Shows Promise in Small Trial

    Read More

    Follow these Magazines to stay up-to-date on the latest in medical innovations and the issues that could affect your health.

More stories from Medicine